On the 16th, TAHO Pharmaceuticals, a biotech company listed on the Emerging Stock Board, announced that all participants in the U.S. Phase III clinical trial for its anti-thrombotic oral dissolving film (ODF) drug, TAH3311, have completed dosing. This marks a significant milestone for the 505(b)(2) regulatory pathway, aimed at bringing a new drug formulation to market. The trial recruited 60 healthy participants and was designed based on U.S. FDA-approved bioequivalence (BE) standards to compare plasma concentrations with the original tablet formulation. Following the completion of the clinical trial data report in the second quarter of 2025, TAHO plans to apply for drug approvals in the U.S. and Europe in the third quarter of 2025 while actively seeking international marketing partners to expand its global market presence.
Read more
